Clinical Study Data in Prostate Cancer Genomic Testing

A key opinion leader provides an overview of study data investigating the clinical validity and clinical utility of the currently available genomic testing options in prostate cancer.

EP: 1.Staging, Grading, and Risk Stratification of Prostate Cancer

EP: 2.Treatment Options for High-Risk, Clinically Localized Prostate Cancer

EP: 3.Clinical Challenges Surrounding Treatment Decision-Making in Clinically Localized Prostate Cancer

EP: 4.The Potential for Overtreatment or Undertreatment of Prostate Cancer

EP: 5.Addressing Clinical Challenges of Prostate Cancer Management with the Use of Genomic Testing

EP: 6.Available Genomic Tests for Clinically Localized Prostate Cancer

Now Viewing

EP: 7.Clinical Study Data in Prostate Cancer Genomic Testing

EP: 8.Clinical Implications of Using Genomic Testing Results in Prostate Cancer Risk-Stratification and Treatment Selection

EP: 9.Exciting Emerging Data in Prostate Cancer

Related Videos

Related Content

Advertisement

June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke

ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke

In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.

June 6th 2025

Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis

Michael S. Cookson, MD, MMHC, FACS

"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.

Related Content

Advertisement

June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke

ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.

April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.

June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke

In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.

June 6th 2025

Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis

Michael S. Cookson, MD, MMHC, FACS

"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.